%0 Journal Article %T Impact of performance status and age on osimertinib efficacy in patients with EGFR -mutant T790M-positive non-small-cell lung cancer %A Lamberti, Giuseppe %A Andrini, Elisa %A Ricciuti, Biagio %J Journal of Thoracic Disease %D 2019 %B 2019 %9 %! Impact of performance status and age on osimertinib efficacy in patients with EGFR -mutant T790M-positive non-small-cell lung cancer %K %X Activating epidermal growth factor receptor ( EGFR ) mutations are reported in 30–40% of Asiatic patients and in 10–15% of unselected Caucasian patients with advanced non-small cell lung cancer (NSCLC) (1). %U https://jtd.amegroups.org/article/view/31345 %P S1831-S1834 %@ 2077-6624